A Phase 2 Study of Etrumadenant and Zimberelimab Immunotherapy to Treat Dedifferentiated Liposarcoma


Full Title

A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination with Anti-PD-1 Therapy (AB122) in Patients with Advanced Dedifferentiated Liposarcoma


The purpose of this study is to see if etrumadenant and zimberelimab are useful for treating advanced dedifferentiated liposarcoma (DDLS). Researchers want to see if the two drugs together are safe and can shrink DDLS.

Etrumadenant blocks adenosine, a substance made inside tumors. Adenosine is involved in tumor growth and may dampen the immune response against cancer. Blocking adenosine may boost the immune system to fight cancer cells. Zimberelimab also helps the immune system target cancer cells, leading to cancer cell death. Etrumadenant is taken orally (by mouth) and zimberelimab is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have DDLS that came back after treatment, spread to other parts of your body, or cannot be removed with surgery.
  • Have completed prior treatment at least 4 weeks before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please contact Dr. Sandra P. D’Angelo’s office at 646-888-4159.




Phase II (phase 2)

Disease Status

Relapsed or Refractory